Durable clinical benefit to trastuzumab and chemotherapy in a patient with metastatic colon adenocarcinoma harboring ERBB2 amplification

Somatic ERBB2 amplification or activating mutations occur in approximately 2–5% of metastatic colorectal adenocarcinomas and are presumed to be oncogenic drivers, but limited evidence exists to suggest these lesions are sensitive to targeted monotherapy in patients. Here we present the case of a pat...

Descripción completa

Detalles Bibliográficos
Autores principales: Disel, Umut, Germain, Alexis, Yilmazel, Bahar, Abali, Huseyin, Bolat, Filiz Aka, Yelensky, Roman, Elvin, Julia A., Lipson, Doron, Chmielecki, Juliann, Wang, Kai, Stephens, Philip J., Ross, Jeffrey S., Miller, Vincent A., Ali, Siraj M., George, Thomas J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506361/
https://www.ncbi.nlm.nih.gov/pubmed/26244165

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4506361/
https://www.ncbi.nlm.nih.gov/pubmed/26244165

Ejemplares similares